In April 2025, we marked a significant milestone in our journey as a CRO for vaccine clinical trials in Africa. We proudly opened two new offices on the African continent, in Nairobi, Kenya and Accra, Ghana. These openings represent more than geographic expansion but an intent to invest in regional capacity, to deepen meaningful partnerships, and to deliver impactful locally grounded research that advances public health of the region. These launches strengthen our ability to service clients, communities, and collaborators with even greater proximity and purpose.
Africa has long played a central role in P95’s global work. With a deep-rooted history of collaboration across Sub-Saharan Africa, the launch of these two permanent offices is both a natural evolution and a powerful reaffirmation of our long-term vision.
Celebrating Our Kenya Office Launch
On 8 April 2025, our Nairobi office was officially opened in a celebration that blended professionalism with joy. P95 staff members, collaborators, and friends gathered to mark the occasion with a cocktail evening, a light-hearted bingo game, and reflections on the work ahead.
The Kenya office strengthens our presence in East Africa and enhances our ability to support local clinical trials, collaborate with healthcare institutions, and work closely with regulators and academic researchers. It also creates new opportunities for capacity-building, training, and direct involvement with local communities. As a CRO for vaccine clinical trials in Africa, this expansion allows P95 to tailor its services more precisely to local contexts and public health priorities.
“It has been a privilege to take part in the official launches made possible by the dedication and hard work of the local teams. I had the honour of meeting many skilled and committed professionals during our insightful site visits and networking events. I am confident that our presence will contribute meaningfully to the growth of both regions.” – Laurence de Moerlooze, Chief Medical Officer
lAUNCHING OUR OFFICE IN Ghana
Just two days later, on 10 April 2025, P95 officially opened its Ghana office in Accra. The launch celebration brought together staff members, local collaborators, and clinical site partners to reflect on a shared commitment to public health across West Africa.
This office marks our fourth physical presence on the continent, alongside Johannesburg, Morocco and Nairobi, and solidifies Ghana as our strategic base for the West African region. From Accra, we will expand our operational reach and partner with regional health stakeholders to deliver high-quality clinical and epidemiological studies. These efforts further establish P95 as a trusted CRO for vaccine clinical trials in Africa, equipped to support both multinational sponsors and regional health systems.
Clinical Site Visits: Grounding Our Work in Local Collaboration
Beyond ribbon cuttings and celebrations, the week was filled with meaningful site visits in both Kenya and Ghana. P95 leadership and project teams visited active clinical research sites to engage directly with the healthcare providers and investigators conducting ongoing studies.
These visits are a cornerstone of how we operate. They demonstrate our commitment to investing in local knowledge, understanding context, and building partnerships based on mutual trust.
Media Spotlight: Sharing Our Vision with Ghana
As part of the Ghana launch, P95 was invited for a live radio interview with one of the country’s leading media outlets. The interview, which included leaders from our clinical and operational teams, provided an opportunity to explain who we are, what we do, and why our work matters.
Investing in Local Talent and Infrastructure
One of the core messages shared throughout both launches was that P95 is not here to “come in and leave.” We are here to stay, to grow with our partners, and to support the development of sustainable health research ecosystems. By opening permanent offices, we are increasing our footprint, hiring full-time staff, offering internships, and transferring knowledge that stays within the region.
“P95’s presence in Kenya and Ghana represents a significant investment in the clinical research ecosystem, that will ensure the inclusion of African sites in clinical trials. Our commitment to developing local expertise provides young graduates in the clinical research field with valuable opportunities to contribute to Africa’s research agenda.” – Edward Sobe Yarig, Regional Operations Lead West Africa
As one of the few CROs for vaccine clinical trials in Africa with permanent offices, we are in a strong position to build meaningful partnerships and foster regional leadership in clinical research. Our goal is to elevate local capabilities while working alongside global teams to ensure that the insights generated reflect the realities of the communities involved.
Looking ahead: A shared future in africa
These new offices in Kenya and Ghana are part of a larger strategy to support high-quality research where it is needed most. Whether it’s evaluating vaccine effectiveness, supporting early-phase trials, or conducting pragmatic observational studies, we are building the infrastructure, networks, and relationships required to deliver with excellence.
The response from our partners has been overwhelmingly positive which provides a testament to the trust we have built and the momentum we are carrying forward.
“The collective P95 African management team has demonstrated a longstanding and sustainable approach to developing clinical trials within the African continent, supported by both clients and site staff alike. Establishing formal offices in the continent, outside of South Africa, is the next logical step in this rewarding and important endeavour.” – Catherine Lund, VP Strategic Development Africa
Learn more about our expertise in Africa and low- and middle-income countries (LMICs)
0 Comments